[{"orgOrder":0,"company":"GBI","sponsor":"Allterum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"4A10","moa":"IL-7R?","graph1":"Oncology","graph2":"Preclinical","graph3":"GBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBI \/ Allterum Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GBI \/ Allterum Therapeutics"},{"orgOrder":0,"company":"GBI","sponsor":"NanoRetinal","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"NAR-001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"GBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBI \/ NanoRetinal","highestDevelopmentStatusID":"4","companyTruncated":"GBI \/ NanoRetinal"}]

Find Clinical Drug Pipeline Developments & Deals by GBI

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The partnership to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (IRD).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 09, 2025

                          Lead Product(s) : NAR-001

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : NanoRetinal

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The collaboration aims to advance Allterum's lead candidate 4A10, a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers, into clinic.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : 4A10

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Allterum Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank